About Antiverse

Antiverse combines artificial intelligence with cell line engineering to design antibodies against drug targets that have been difficult to reach. The company focuses on G-protein coupled receptors and ion channels, using machine learning to predict high-binding antibody sequences without pre-existing data. This moves from target identification to functional antibody in six months. Pharmaceutical and biotech organisations partner with Antiverse to accelerate antibody discovery programmes. The platform screens target-specific libraries against unique cell lines, then uses multiparameter clustering across twenty properties to identify lead candidates. This addresses unmet needs in drug discovery and aims to bring new therapies to patients.